Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors.

Literature DB >> 9505091

Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors.

T Brocker¹, K Karjalainen.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1998 PMID： 9505091 DOI： 10.1016/s0065-2776(08)60561-1

Source DB: PubMed Journal: Adv Immunol ISSN： 0065-2776 Impact factor: 3.543

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

1. Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors: David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal: Hum Gene Ther Date: 2011-09-23 Impact factor: 5.695

Review 2. Immunotherapy for ovarian cancer: what's next?

Authors: Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544

3. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.

Authors: David M Barrett; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal: Hum Gene Ther Date: 2013-08 Impact factor: 5.695

4. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.

Authors: Thomas M J Niederman; Zoher Ghogawala; Bob S Carter; Hillary S Tompkins; Margaret M Russell; Richard C Mulligan
Journal: Proc Natl Acad Sci U S A Date: 2002-05-07 Impact factor: 11.205

5. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

Authors: Xiufeng Wu; Arlene J Sereno; Flora Huang; Kai Zhang; Micheal Batt; Jonathan R Fitchett; Dongmei He; Heather L Rick; Elaine M Conner; Stephen J Demarest
Journal: MAbs Date: 2015 Impact factor: 5.857

6. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Authors: A D Gritzapis; A Mamalaki; A Kretsovali; J Papamatheakis; M Belimezi; S A Perez; C N Baxevanis; M Papamichail
Journal: Br J Cancer Date: 2003-04-22 Impact factor: 7.640

Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors.

1. Treatment of advanced leukemia in mice with mRNA engineered T cells.

Review 2. Immunotherapy for ovarian cancer: what's next?

3. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.

4. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.

5. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

6. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Review 7. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Review 8. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Review 9. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

10. A new approach to produce IgG₄-like bispecific antibodies.

Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors.

1. Treatment of advanced leukemia in mice with mRNA engineered T cells.

Review 2. Immunotherapy for ovarian cancer: what's next?

3. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.

4. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.

5. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

6. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Review 7. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Review 8. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Review 9. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

10. A new approach to produce IgG4-like bispecific antibodies.

10. A new approach to produce IgG₄-like bispecific antibodies.